Australian patients with the most common form of lymphoma will for the first time have access to affordable, at-home treatment options after the federal subsidisation of an injectable immunotherapy.

Galapagos reported promising results from ATALANTA-1 study show 100% ORR/CR for relapsed Mantle Cell Lymphoma. Click for GLPG ...

Caribou is scaling back its operations, halting multiple programmes, and cutting staff to focus on two cancer programmes.

Shares of Caribou Biosciences (NASDAQ:CRBU) will be in focus on Friday after the gene-editing biotech announced plans to ...

The CRISPR company is laying off about a third of its employees and stopping work on an experimental lupus treatment in a bid ...

Limited’s stock price, history, target price and what caused it to recently dip, let’s take a look at some background.

In a Phase 1b/2a trial for lymphoma and cytokine release syndrome, the first group's dose-limiting toxicity observation ...

Dizal (SSE:688192), a biopharmaceutical company committed to developing novel medicines for the treatment of cancer and ...

During a live event, Nathan M. Denlinger, DO, MS, discussed the TRANSFORM trial of lisocabtagene maraleucel in B-cell ...

CURE provides access to the cancer news, latest oncology research & expert insights that serve as a guide to every stage of the cancer experience.

Diffuse large B-cell lymphoma (DLBCL) is the most common and fast-growing type of non-Hodgkin lymphoma, a cancer that affects ...